当前位置: X-MOL 学术Annu. Rev. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease.
Annual Review of Medicine ( IF 10.5 ) Pub Date : 2018-10-24 , DOI: 10.1146/annurev-med-041717-085853
Erica P Young 1 , Nathan O Stitziel 1, 2, 3
Affiliation  

Coronary artery disease (CAD) is a major cause of morbidity and mortality. Unfortunately, despite decades of research focused on disease pathogenesis, we still lack a sufficient pharmacopeia for preventing CAD. The failure of many novel cardiovascular drugs to improve clinical outcomes reflects the major substantial challenge of drug development: identifying causal mechanisms that can be therapeutically manipulated to lower disease risk. Identifying genetic variants that are associated with risk of CAD has emerged as a clear path toward improving our understanding of the underlying mechanisms that lead to disease and to the development of new therapies. Here, we review the potential utility and limitations of using human genetics to guide the identification of therapeutic targets for CAD.

中文翻译:

充分利用人类遗传学的见识,确定冠状动脉疾病的新型治疗靶标。

冠状动脉疾病(CAD)是发病率和死亡率的主要原因。不幸的是,尽管数十年来的研究都集中在疾病的发病机理上,但我们仍然缺乏足够的药典来预防CAD。许多新型心血管药物未能改善临床结果,这反映出药物开发的重大挑战:确定可通过治疗手段降低疾病风险的因果机制。鉴定与CAD风险相关的遗传变异已成为一条清晰的途径,可以帮助我们更好地理解导致疾病和开发新疗法的潜在机制。在这里,我们回顾了使用人类遗传学来指导CAD治疗靶标识别的潜在效用和局限性。
更新日期:2019-01-28
down
wechat
bug